| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transforming Growth Factor beta | 9 | 2019 | 1961 | 1.910 |
Why?
|
| Neuropeptides | 9 | 2024 | 944 | 1.830 |
Why?
|
| Integrins | 7 | 2019 | 834 | 1.640 |
Why?
|
| Peptide Hormones | 7 | 2021 | 132 | 1.410 |
Why?
|
| Trichinella spiralis | 3 | 2019 | 22 | 1.190 |
Why?
|
| Panic Disorder | 23 | 2013 | 613 | 1.180 |
Why?
|
| Trichinellosis | 2 | 2019 | 27 | 1.100 |
Why?
|
| Enteroendocrine Cells | 2 | 2017 | 78 | 1.020 |
Why?
|
| Hypothalamus | 7 | 2021 | 999 | 0.970 |
Why?
|
| Dendritic Cells | 6 | 2019 | 2747 | 0.930 |
Why?
|
| Helminths | 2 | 2023 | 39 | 0.920 |
Why?
|
| Trichuriasis | 5 | 2023 | 24 | 0.900 |
Why?
|
| Anxiety Disorders | 19 | 2021 | 2720 | 0.900 |
Why?
|
| Anti-Anxiety Agents | 5 | 2022 | 397 | 0.830 |
Why?
|
| Th2 Cells | 2 | 2020 | 1060 | 0.790 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2021 | 24 | 0.770 |
Why?
|
| Immune System | 3 | 2015 | 796 | 0.680 |
Why?
|
| Trichuris | 4 | 2023 | 32 | 0.680 |
Why?
|
| Helminthiasis | 1 | 2020 | 81 | 0.670 |
Why?
|
| Hypothalamic Hormones | 2 | 2017 | 145 | 0.670 |
Why?
|
| Lanthanoid Series Elements | 1 | 2019 | 17 | 0.660 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 3032 | 0.650 |
Why?
|
| Organ of Corti | 1 | 2018 | 85 | 0.620 |
Why?
|
| Calcium-Binding Proteins | 4 | 2024 | 1069 | 0.620 |
Why?
|
| Anxiety | 7 | 2022 | 4573 | 0.620 |
Why?
|
| Clonazepam | 6 | 2022 | 135 | 0.610 |
Why?
|
| Intestinal Diseases, Parasitic | 3 | 2013 | 64 | 0.600 |
Why?
|
| Antipsychotic Agents | 14 | 2021 | 3067 | 0.550 |
Why?
|
| Phobic Disorders | 13 | 2013 | 439 | 0.540 |
Why?
|
| Vestibule, Labyrinth | 1 | 2018 | 234 | 0.540 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2015 | 3080 | 0.530 |
Why?
|
| Fluoxetine | 14 | 2006 | 733 | 0.520 |
Why?
|
| Parasitic Diseases | 1 | 2016 | 76 | 0.520 |
Why?
|
| Nervous System | 1 | 2019 | 545 | 0.520 |
Why?
|
| Receptors, Neuropeptide | 3 | 2022 | 106 | 0.510 |
Why?
|
| Host-Parasite Interactions | 2 | 2015 | 300 | 0.470 |
Why?
|
| Inflammation | 6 | 2019 | 10773 | 0.440 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 3 | 2008 | 64 | 0.440 |
Why?
|
| Depressive Disorder | 19 | 2012 | 3728 | 0.440 |
Why?
|
| Nerve Tissue Proteins | 5 | 2024 | 4414 | 0.430 |
Why?
|
| Antidepressive Agents, Second-Generation | 10 | 2007 | 489 | 0.430 |
Why?
|
| Intestine, Small | 1 | 2019 | 1206 | 0.420 |
Why?
|
| Telefacsimile | 1 | 2012 | 4 | 0.410 |
Why?
|
| Th17 Cells | 1 | 2019 | 794 | 0.410 |
Why?
|
| Tosyl Compounds | 1 | 2012 | 115 | 0.410 |
Why?
|
| Cochlea | 1 | 2018 | 845 | 0.400 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2012 | 158 | 0.400 |
Why?
|
| Haloperidol | 4 | 2019 | 389 | 0.400 |
Why?
|
| Postal Service | 1 | 2012 | 96 | 0.390 |
Why?
|
| Antidepressive Agents | 11 | 2006 | 2897 | 0.390 |
Why?
|
| GABA Modulators | 3 | 2022 | 109 | 0.390 |
Why?
|
| Enteritis | 1 | 2013 | 162 | 0.380 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2022 | 8181 | 0.380 |
Why?
|
| General Practitioners | 1 | 2012 | 101 | 0.360 |
Why?
|
| Psoriasis | 5 | 2016 | 950 | 0.360 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 656 | 0.350 |
Why?
|
| Intestines | 3 | 2016 | 1909 | 0.340 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2003 | 357 | 0.340 |
Why?
|
| Anilides | 1 | 2012 | 411 | 0.330 |
Why?
|
| Pro-Opiomelanocortin | 2 | 2020 | 140 | 0.320 |
Why?
|
| Synapses | 1 | 2018 | 1769 | 0.320 |
Why?
|
| Citalopram | 4 | 2020 | 402 | 0.310 |
Why?
|
| Lateral Ventricles | 2 | 2021 | 146 | 0.310 |
Why?
|
| Anorexia Nervosa | 1 | 2017 | 1361 | 0.310 |
Why?
|
| Animals | 39 | 2024 | 168459 | 0.310 |
Why?
|
| Forkhead Transcription Factors | 3 | 2016 | 1616 | 0.300 |
Why?
|
| Cerebral Hemorrhage | 2 | 2021 | 2656 | 0.300 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2021 | 286 | 0.300 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 726 | 0.300 |
Why?
|
| Retina | 1 | 2018 | 2659 | 0.290 |
Why?
|
| Nitriles | 1 | 2012 | 971 | 0.290 |
Why?
|
| Brain Stem | 3 | 2021 | 858 | 0.280 |
Why?
|
| Communicable Diseases | 1 | 2015 | 875 | 0.280 |
Why?
|
| Rats | 15 | 2022 | 23742 | 0.270 |
Why?
|
| Arthritis, Rheumatoid | 9 | 2013 | 3763 | 0.270 |
Why?
|
| Clozapine | 4 | 2019 | 504 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 1405 | 0.260 |
Why?
|
| Receptors, Neurotransmitter | 2 | 2023 | 174 | 0.250 |
Why?
|
| Cytokines | 6 | 2023 | 7396 | 0.240 |
Why?
|
| Piperazines | 7 | 2011 | 2523 | 0.240 |
Why?
|
| DNA-Binding Proteins | 3 | 2017 | 9606 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2016 | 15936 | 0.240 |
Why?
|
| Data Collection | 2 | 2012 | 3322 | 0.230 |
Why?
|
| Male | 111 | 2024 | 360804 | 0.230 |
Why?
|
| Depressive Disorder, Major | 10 | 2018 | 4761 | 0.230 |
Why?
|
| Epithelial Cells | 1 | 2016 | 3673 | 0.230 |
Why?
|
| Immunity, Innate | 1 | 2016 | 3065 | 0.220 |
Why?
|
| Benzodiazepines | 8 | 2016 | 1132 | 0.220 |
Why?
|
| Humans | 130 | 2024 | 761504 | 0.210 |
Why?
|
| Brain | 10 | 2023 | 27112 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 18 | 2016 | 17904 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 28 | 2011 | 6019 | 0.200 |
Why?
|
| Antiparkinson Agents | 1 | 2002 | 184 | 0.190 |
Why?
|
| Galanin | 1 | 2021 | 42 | 0.190 |
Why?
|
| Triazoles | 2 | 1998 | 903 | 0.190 |
Why?
|
| Paroxetine | 3 | 2008 | 182 | 0.190 |
Why?
|
| Chlorpromazine | 1 | 2021 | 111 | 0.190 |
Why?
|
| Receptors, Galanin | 1 | 2020 | 4 | 0.190 |
Why?
|
| Traumatology | 1 | 2001 | 100 | 0.180 |
Why?
|
| Hospital Mortality | 1 | 2014 | 5294 | 0.180 |
Why?
|
| Personality Disorders | 3 | 2002 | 722 | 0.180 |
Why?
|
| Telomere | 2 | 2018 | 943 | 0.170 |
Why?
|
| Craniocerebral Trauma | 2 | 2001 | 490 | 0.170 |
Why?
|
| Neurons | 7 | 2024 | 9463 | 0.170 |
Why?
|
| Neck Injuries | 1 | 2001 | 160 | 0.170 |
Why?
|
| Hydrogen Sulfide | 1 | 2021 | 141 | 0.170 |
Why?
|
| Neurochemistry | 1 | 2019 | 29 | 0.170 |
Why?
|
| Receptors, Somatostatin | 1 | 2020 | 136 | 0.170 |
Why?
|
| Adult | 83 | 2018 | 221177 | 0.170 |
Why?
|
| Protein Kinase C | 1 | 2004 | 1202 | 0.170 |
Why?
|
| HLA-DR Antigens | 4 | 2008 | 602 | 0.160 |
Why?
|
| Tranexamic Acid | 1 | 2021 | 176 | 0.160 |
Why?
|
| Aromatase | 1 | 2019 | 147 | 0.160 |
Why?
|
| Quinolones | 3 | 2008 | 378 | 0.160 |
Why?
|
| Cyclohexanols | 3 | 2007 | 126 | 0.160 |
Why?
|
| Septal Nuclei | 1 | 2019 | 85 | 0.150 |
Why?
|
| Sexual and Gender Disorders | 1 | 1998 | 6 | 0.150 |
Why?
|
| Medical Waste Disposal | 1 | 2018 | 14 | 0.150 |
Why?
|
| Hippocampus | 5 | 2021 | 3766 | 0.150 |
Why?
|
| Digestion | 1 | 2017 | 53 | 0.150 |
Why?
|
| RNA, Messenger | 6 | 2022 | 12795 | 0.150 |
Why?
|
| Carbon Monoxide | 1 | 2021 | 547 | 0.150 |
Why?
|
| Female | 97 | 2019 | 392644 | 0.140 |
Why?
|
| Gene Expression Regulation | 8 | 2020 | 11903 | 0.140 |
Why?
|
| Middle Aged | 70 | 2018 | 220895 | 0.140 |
Why?
|
| Apoptosis | 2 | 2012 | 9486 | 0.140 |
Why?
|
| Oxytocin | 1 | 2021 | 402 | 0.140 |
Why?
|
| Scleroderma, Limited | 1 | 2016 | 8 | 0.140 |
Why?
|
| Mice | 13 | 2023 | 81525 | 0.140 |
Why?
|
| Diencephalon | 1 | 2016 | 54 | 0.140 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 695 | 0.140 |
Why?
|
| Homeostasis | 3 | 2023 | 3323 | 0.130 |
Why?
|
| Comorbidity | 17 | 2014 | 10508 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2020 | 549 | 0.130 |
Why?
|
| Signal Transduction | 8 | 2021 | 23445 | 0.130 |
Why?
|
| N-Methylaspartate | 1 | 2016 | 231 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2016 | 4369 | 0.130 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2016 | 579 | 0.130 |
Why?
|
| Piracetam | 2 | 2007 | 88 | 0.130 |
Why?
|
| Interleukins | 2 | 2011 | 782 | 0.130 |
Why?
|
| Age of Onset | 9 | 2016 | 3305 | 0.130 |
Why?
|
| Toes | 1 | 2016 | 209 | 0.130 |
Why?
|
| Gene Frequency | 10 | 2016 | 3606 | 0.120 |
Why?
|
| Sentinel Surveillance | 1 | 2017 | 291 | 0.120 |
Why?
|
| Severity of Illness Index | 22 | 2012 | 15842 | 0.120 |
Why?
|
| Neurogenesis | 2 | 2021 | 863 | 0.120 |
Why?
|
| Exodeoxyribonucleases | 1 | 2016 | 192 | 0.120 |
Why?
|
| New South Wales | 1 | 2014 | 69 | 0.120 |
Why?
|
| Up-Regulation | 5 | 2016 | 4124 | 0.120 |
Why?
|
| Thiophenes | 3 | 2010 | 569 | 0.120 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2001 | 807 | 0.120 |
Why?
|
| Gene Expression | 4 | 2021 | 7581 | 0.120 |
Why?
|
| Australia | 3 | 2017 | 1250 | 0.120 |
Why?
|
| Emergency Medical Services | 2 | 2008 | 1923 | 0.120 |
Why?
|
| Hospitalization | 1 | 2014 | 10723 | 0.120 |
Why?
|
| Synaptic Transmission | 1 | 2021 | 1173 | 0.120 |
Why?
|
| Nortriptyline | 3 | 2003 | 79 | 0.120 |
Why?
|
| Decision Support Techniques | 2 | 2001 | 1998 | 0.120 |
Why?
|
| Haplotypes | 6 | 2008 | 2713 | 0.120 |
Why?
|
| Indoles | 1 | 2002 | 1833 | 0.120 |
Why?
|
| Treatment Outcome | 33 | 2017 | 64680 | 0.120 |
Why?
|
| Immunity, Mucosal | 1 | 2017 | 483 | 0.110 |
Why?
|
| Antidepressive Agents, Tricyclic | 4 | 2003 | 432 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2021 | 18965 | 0.110 |
Why?
|
| Water Pollutants, Chemical | 1 | 2018 | 359 | 0.110 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2014 | 178 | 0.110 |
Why?
|
| Amide Synthases | 1 | 2013 | 14 | 0.110 |
Why?
|
| Mice, Knockout | 4 | 2013 | 14414 | 0.110 |
Why?
|
| Genes, rel | 1 | 2013 | 9 | 0.110 |
Why?
|
| Interleukin-2 | 2 | 2011 | 1889 | 0.110 |
Why?
|
| Fingers | 1 | 2016 | 507 | 0.110 |
Why?
|
| Personality Development | 3 | 2001 | 244 | 0.110 |
Why?
|
| Psychometrics | 5 | 2012 | 3065 | 0.110 |
Why?
|
| Corpus Striatum | 2 | 2016 | 1235 | 0.110 |
Why?
|
| Anticonvulsants | 3 | 2009 | 1906 | 0.110 |
Why?
|
| Sertraline | 3 | 2009 | 209 | 0.100 |
Why?
|
| Double-Blind Method | 14 | 2011 | 12341 | 0.100 |
Why?
|
| Host Specificity | 1 | 2013 | 57 | 0.100 |
Why?
|
| Models, Immunological | 1 | 2015 | 513 | 0.100 |
Why?
|
| Protein Subunits | 1 | 2016 | 943 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 1250 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 1076 | 0.100 |
Why?
|
| Thrombectomy | 1 | 2017 | 705 | 0.100 |
Why?
|
| Neocortex | 1 | 2016 | 417 | 0.100 |
Why?
|
| Genotype | 13 | 2016 | 12990 | 0.100 |
Why?
|
| Drug Resistance | 7 | 2009 | 1596 | 0.100 |
Why?
|
| Bupropion | 2 | 2006 | 304 | 0.100 |
Why?
|
| Ambulatory Care | 12 | 2011 | 2775 | 0.100 |
Why?
|
| Personality Inventory | 6 | 2008 | 1019 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 1897 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 2021 | 2135 | 0.100 |
Why?
|
| Caffeine | 1 | 1996 | 700 | 0.100 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2013 | 174 | 0.100 |
Why?
|
| Depression | 5 | 2018 | 8124 | 0.100 |
Why?
|
| Antigens, Helminth | 1 | 2011 | 68 | 0.100 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 1164 | 0.100 |
Why?
|
| Response Elements | 1 | 2013 | 309 | 0.100 |
Why?
|
| Nicotine | 1 | 1996 | 680 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2004 | 418 | 0.090 |
Why?
|
| Environmental Monitoring | 1 | 2018 | 1460 | 0.090 |
Why?
|
| Cell Count | 1 | 2015 | 1835 | 0.090 |
Why?
|
| Interleukin-13 | 1 | 2013 | 392 | 0.090 |
Why?
|
| Drive | 1 | 2011 | 34 | 0.090 |
Why?
|
| Drug Therapy, Combination | 11 | 2008 | 6310 | 0.090 |
Why?
|
| Integrin alpha Chains | 1 | 2011 | 95 | 0.090 |
Why?
|
| Azabicyclo Compounds | 1 | 2011 | 68 | 0.090 |
Why?
|
| Mesoderm | 1 | 2014 | 674 | 0.090 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 1458 | 0.090 |
Why?
|
| Arthritis | 2 | 2007 | 680 | 0.090 |
Why?
|
| Grief | 1 | 2013 | 254 | 0.090 |
Why?
|
| Cryopreservation | 1 | 2015 | 728 | 0.090 |
Why?
|
| Prescription Drugs | 1 | 2018 | 631 | 0.090 |
Why?
|
| Agoraphobia | 3 | 2007 | 177 | 0.090 |
Why?
|
| Ethanol | 1 | 1996 | 1324 | 0.090 |
Why?
|
| Selection Bias | 1 | 2012 | 359 | 0.090 |
Why?
|
| Polymorphism, Genetic | 5 | 2007 | 4243 | 0.090 |
Why?
|
| Alprazolam | 1 | 2010 | 102 | 0.090 |
Why?
|
| Fibronectins | 1 | 2014 | 723 | 0.090 |
Why?
|
| Multiple Sclerosis | 2 | 2008 | 3220 | 0.090 |
Why?
|
| Meditation | 1 | 2013 | 251 | 0.090 |
Why?
|
| Amygdala | 1 | 2018 | 1354 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 1408 | 0.090 |
Why?
|
| Chest Pain | 1 | 1997 | 1091 | 0.090 |
Why?
|
| Aged | 34 | 2018 | 169289 | 0.090 |
Why?
|
| Telomerase | 1 | 2015 | 745 | 0.090 |
Why?
|
| Arthritis, Psoriatic | 2 | 2016 | 219 | 0.090 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2010 | 899 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 11118 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 894 | 0.080 |
Why?
|
| Imagination | 1 | 2011 | 226 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2014 | 2281 | 0.080 |
Why?
|
| Facial Expression | 1 | 2013 | 508 | 0.080 |
Why?
|
| Ovalbumin | 1 | 2011 | 677 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 6 | 2019 | 22169 | 0.080 |
Why?
|
| Alleles | 9 | 2008 | 6863 | 0.080 |
Why?
|
| Taxoids | 1 | 2012 | 668 | 0.080 |
Why?
|
| Propranolol | 1 | 2011 | 489 | 0.080 |
Why?
|
| Awareness | 1 | 2013 | 648 | 0.080 |
Why?
|
| Lithium | 3 | 2003 | 596 | 0.080 |
Why?
|
| Reminder Systems | 1 | 2012 | 388 | 0.080 |
Why?
|
| Age Distribution | 1 | 2014 | 2880 | 0.080 |
Why?
|
| Bereavement | 1 | 2013 | 308 | 0.080 |
Why?
|
| Arousal | 2 | 2013 | 1166 | 0.080 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2008 | 36 | 0.080 |
Why?
|
| Peptides, Cyclic | 2 | 2008 | 392 | 0.080 |
Why?
|
| Nipecotic Acids | 1 | 2008 | 36 | 0.080 |
Why?
|
| Tretinoin | 1 | 2011 | 519 | 0.080 |
Why?
|
| Metabolome | 1 | 2015 | 989 | 0.080 |
Why?
|
| Cell Communication | 1 | 2015 | 1657 | 0.080 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 2084 | 0.070 |
Why?
|
| Dibenzothiazepines | 1 | 2008 | 102 | 0.070 |
Why?
|
| Ischemia | 1 | 2016 | 1882 | 0.070 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2009 | 186 | 0.070 |
Why?
|
| Rheumatoid Factor | 1 | 2008 | 185 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2448 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 4 | 2007 | 5789 | 0.070 |
Why?
|
| Psychiatry | 1 | 1999 | 1693 | 0.070 |
Why?
|
| Time Factors | 6 | 2021 | 39967 | 0.070 |
Why?
|
| Mice, SCID | 1 | 2012 | 2626 | 0.070 |
Why?
|
| Valproic Acid | 2 | 2003 | 443 | 0.070 |
Why?
|
| Varicose Ulcer | 1 | 2007 | 55 | 0.070 |
Why?
|
| Chronic Disease | 5 | 2016 | 9318 | 0.070 |
Why?
|
| HLA-C Antigens | 1 | 2007 | 140 | 0.070 |
Why?
|
| Adolescent | 27 | 2017 | 88319 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 3712 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2007 | 168 | 0.070 |
Why?
|
| Case-Control Studies | 11 | 2016 | 22176 | 0.070 |
Why?
|
| Colitis | 1 | 2015 | 1233 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 1886 | 0.070 |
Why?
|
| Neutrophils | 1 | 2019 | 3767 | 0.070 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2013 | 4575 | 0.070 |
Why?
|
| Cathepsin D | 1 | 2006 | 59 | 0.070 |
Why?
|
| Stress, Psychological | 4 | 2013 | 4481 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2011 | 1081 | 0.060 |
Why?
|
| Drug Administration Schedule | 9 | 2008 | 4853 | 0.060 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2005 | 68 | 0.060 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2010 | 625 | 0.060 |
Why?
|
| Exons | 2 | 2008 | 2391 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 1241 | 0.060 |
Why?
|
| Visual Perception | 1 | 2013 | 1387 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2011 | 1802 | 0.060 |
Why?
|
| Sex Factors | 4 | 2014 | 10552 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 6132 | 0.060 |
Why?
|
| Models, Animal | 1 | 2011 | 2112 | 0.060 |
Why?
|
| England | 1 | 2005 | 526 | 0.060 |
Why?
|
| Young Adult | 10 | 2017 | 59243 | 0.060 |
Why?
|
| Hydrolases | 1 | 2005 | 147 | 0.060 |
Why?
|
| Stroke | 3 | 2021 | 9757 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 3602 | 0.060 |
Why?
|
| Behcet Syndrome | 1 | 2005 | 86 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2021 | 7856 | 0.060 |
Why?
|
| Cause of Death | 1 | 2014 | 3683 | 0.060 |
Why?
|
| Protein Kinase C-alpha | 1 | 2004 | 113 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2021 | 10445 | 0.060 |
Why?
|
| Risperidone | 1 | 2006 | 381 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2012 | 2495 | 0.050 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 2183 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2004 | 258 | 0.050 |
Why?
|
| S-Adenosylmethionine | 1 | 2004 | 218 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2013 | 2601 | 0.050 |
Why?
|
| Autoantibodies | 3 | 2008 | 2116 | 0.050 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2014 | 1642 | 0.050 |
Why?
|
| Peptides | 1 | 2015 | 4358 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 18252 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 1179 | 0.050 |
Why?
|
| Osteoarthritis | 1 | 2010 | 1063 | 0.050 |
Why?
|
| Vestibular Diseases | 1 | 2005 | 230 | 0.050 |
Why?
|
| Cell Survival | 1 | 2012 | 5791 | 0.050 |
Why?
|
| Antimanic Agents | 2 | 2003 | 520 | 0.050 |
Why?
|
| Desipramine | 1 | 2002 | 182 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2014 | 2053 | 0.050 |
Why?
|
| Lithium Chloride | 1 | 2002 | 82 | 0.050 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2021 | 28 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 908 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 2422 | 0.050 |
Why?
|
| Aged, 80 and over | 8 | 2017 | 58976 | 0.050 |
Why?
|
| Receptors, Interleukin | 2 | 2004 | 243 | 0.050 |
Why?
|
| Prospective Studies | 12 | 2018 | 54425 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2015 | 4398 | 0.050 |
Why?
|
| Appetite | 2 | 2012 | 247 | 0.050 |
Why?
|
| Weight Loss | 1 | 2013 | 2684 | 0.050 |
Why?
|
| Microsatellite Repeats | 2 | 2001 | 784 | 0.050 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2003 | 297 | 0.050 |
Why?
|
| Supraoptic Nucleus | 1 | 2020 | 28 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2014 | 3548 | 0.050 |
Why?
|
| Obesity | 1 | 2023 | 12947 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 1336 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2011 | 4003 | 0.050 |
Why?
|
| Anemia, Macrocytic | 1 | 2000 | 53 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2013 | 3188 | 0.040 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2020 | 114 | 0.040 |
Why?
|
| Affective Symptoms | 1 | 2003 | 417 | 0.040 |
Why?
|
| Regression Analysis | 4 | 2006 | 6343 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2010 | 10766 | 0.040 |
Why?
|
| Methadone | 1 | 2002 | 321 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 1444 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2002 | 294 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 1996 | 4420 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 3530 | 0.040 |
Why?
|
| Age Factors | 3 | 2014 | 18395 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2009 | 1988 | 0.040 |
Why?
|
| Folic Acid Deficiency | 1 | 2000 | 117 | 0.040 |
Why?
|
| L-Selectin | 1 | 2000 | 209 | 0.040 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2000 | 118 | 0.040 |
Why?
|
| Logistic Models | 3 | 2013 | 13255 | 0.040 |
Why?
|
| Canada | 2 | 2001 | 2122 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.040 |
Why?
|
| Somatoform Disorders | 1 | 2002 | 423 | 0.040 |
Why?
|
| Autoimmune Diseases | 2 | 2008 | 2244 | 0.040 |
Why?
|
| Streptozocin | 1 | 2019 | 194 | 0.040 |
Why?
|
| Bipolar Disorder | 1 | 1996 | 5092 | 0.040 |
Why?
|
| Prolactin | 1 | 2001 | 625 | 0.040 |
Why?
|
| Dyspnea | 1 | 2006 | 1347 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2016 | 2919 | 0.040 |
Why?
|
| Risk Factors | 7 | 2019 | 74206 | 0.040 |
Why?
|
| Placebos | 4 | 2009 | 1667 | 0.040 |
Why?
|
| Quality of Life | 4 | 2013 | 13367 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2021 | 292 | 0.040 |
Why?
|
| Cohort Studies | 7 | 2016 | 41487 | 0.040 |
Why?
|
| Follow-Up Studies | 10 | 2013 | 39106 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2019 | 420 | 0.040 |
Why?
|
| Protein Binding | 1 | 2010 | 9351 | 0.040 |
Why?
|
| Delayed-Action Preparations | 3 | 2008 | 962 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2014 | 23995 | 0.040 |
Why?
|
| Education, Pharmacy | 1 | 2018 | 38 | 0.040 |
Why?
|
| Personality Assessment | 3 | 2011 | 650 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2005 | 2767 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2008 | 2219 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2008 | 4352 | 0.040 |
Why?
|
| Drug Synergism | 4 | 2005 | 1755 | 0.040 |
Why?
|
| Hypothyroidism | 1 | 2002 | 668 | 0.040 |
Why?
|
| Social Behavior Disorders | 1 | 1997 | 96 | 0.030 |
Why?
|
| New Zealand | 1 | 2017 | 358 | 0.030 |
Why?
|
| Hematoma | 1 | 2021 | 768 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2001 | 2155 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2017 | 173 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 1702 | 0.030 |
Why?
|
| Water Supply | 1 | 2018 | 204 | 0.030 |
Why?
|
| Retrospective Studies | 6 | 2014 | 80636 | 0.030 |
Why?
|
| Hostility | 1 | 1996 | 183 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2001 | 2612 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2001 | 937 | 0.030 |
Why?
|
| Proteins | 1 | 2010 | 6032 | 0.030 |
Why?
|
| Expressed Emotion | 1 | 1996 | 92 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 2319 | 0.030 |
Why?
|
| Patient Compliance | 2 | 2002 | 2690 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2002 | 2707 | 0.030 |
Why?
|
| CA2 Region, Hippocampal | 1 | 2015 | 20 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2001 | 980 | 0.030 |
Why?
|
| Sulfones | 1 | 1998 | 448 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2008 | 3745 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 5796 | 0.030 |
Why?
|
| CA3 Region, Hippocampal | 1 | 2015 | 54 | 0.030 |
Why?
|
| Carbolines | 1 | 1997 | 296 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2008 | 3415 | 0.030 |
Why?
|
| Anthelmintics | 1 | 2015 | 83 | 0.030 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2000 | 560 | 0.030 |
Why?
|
| Radiography | 2 | 2005 | 6965 | 0.030 |
Why?
|
| Purines | 1 | 1998 | 607 | 0.030 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2015 | 110 | 0.030 |
Why?
|
| Antigens, CD1 | 1 | 2016 | 439 | 0.030 |
Why?
|
| Dentate Gyrus | 1 | 2015 | 164 | 0.030 |
Why?
|
| Cognition | 2 | 2006 | 6990 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2021 | 888 | 0.030 |
Why?
|
| Cecum | 2 | 2004 | 233 | 0.030 |
Why?
|
| Thinking | 1 | 1996 | 320 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2013 | 12690 | 0.030 |
Why?
|
| Anger | 1 | 1996 | 406 | 0.030 |
Why?
|
| Cell Separation | 1 | 2019 | 1720 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 223 | 0.030 |
Why?
|
| Introns | 1 | 2016 | 981 | 0.030 |
Why?
|
| Prevalence | 8 | 2006 | 15732 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 1119 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 4544 | 0.030 |
Why?
|
| Laminin | 1 | 2014 | 408 | 0.030 |
Why?
|
| Biodiversity | 1 | 2015 | 347 | 0.030 |
Why?
|
| Social Environment | 2 | 2013 | 1020 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 1997 | 1175 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 330 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2014 | 278 | 0.020 |
Why?
|
| Suicide | 1 | 2003 | 1601 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2019 | 5869 | 0.020 |
Why?
|
| Metagenome | 1 | 2015 | 450 | 0.020 |
Why?
|
| Life Change Events | 1 | 1996 | 952 | 0.020 |
Why?
|
| Health Status | 2 | 2006 | 4077 | 0.020 |
Why?
|
| Health Education | 1 | 2018 | 1052 | 0.020 |
Why?
|
| Problem Solving | 1 | 2013 | 441 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2014 | 803 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2001 | 3442 | 0.020 |
Why?
|
| Lod Score | 2 | 2001 | 600 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2004 | 4580 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2013 | 809 | 0.020 |
Why?
|
| Lymphocyte Count | 2 | 2004 | 778 | 0.020 |
Why?
|
| Leukocytes | 1 | 2018 | 2026 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1998 | 4021 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 10209 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13639 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 8529 | 0.020 |
Why?
|
| Yoga | 1 | 2013 | 281 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2001 | 14666 | 0.020 |
Why?
|
| Genetic Linkage | 2 | 2007 | 2341 | 0.020 |
Why?
|
| Immunologic Tests | 1 | 2010 | 104 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2016 | 2203 | 0.020 |
Why?
|
| Relaxation Therapy | 1 | 2010 | 181 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 2206 | 0.020 |
Why?
|
| Galvanic Skin Response | 1 | 2011 | 358 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2013 | 9646 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 306 | 0.020 |
Why?
|
| Physical Chromosome Mapping | 1 | 2008 | 183 | 0.020 |
Why?
|
| Alcoholism | 1 | 1999 | 1973 | 0.020 |
Why?
|
| Speech | 1 | 2013 | 554 | 0.020 |
Why?
|
| Chi-Square Distribution | 3 | 2002 | 3416 | 0.020 |
Why?
|
| Cues | 1 | 2013 | 875 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2012 | 960 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2008 | 247 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2001 | 20570 | 0.020 |
Why?
|
| Linkage Disequilibrium | 2 | 2005 | 1998 | 0.020 |
Why?
|
| Arthritis, Reactive | 1 | 2007 | 20 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2014 | 2048 | 0.020 |
Why?
|
| Opioid-Related Disorders | 1 | 2002 | 2164 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1705 | 0.020 |
Why?
|
| Synovial Membrane | 1 | 2010 | 532 | 0.020 |
Why?
|
| Psychotherapy | 1 | 1996 | 1647 | 0.020 |
Why?
|
| Respiratory Function Tests | 2 | 2006 | 1682 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2012 | 644 | 0.020 |
Why?
|
| Self Concept | 1 | 2013 | 1045 | 0.020 |
Why?
|
| Analysis of Variance | 3 | 2002 | 6228 | 0.020 |
Why?
|
| Reproduction | 1 | 2012 | 645 | 0.020 |
Why?
|
| Single-Blind Method | 2 | 2003 | 1572 | 0.020 |
Why?
|
| Social Behavior | 1 | 2013 | 1135 | 0.020 |
Why?
|
| Aging | 1 | 2006 | 8708 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2014 | 1349 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2016 | 2571 | 0.020 |
Why?
|
| Immunodominant Epitopes | 1 | 2007 | 239 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 2735 | 0.020 |
Why?
|
| Dysthymic Disorder | 1 | 2006 | 75 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 1999 | 3889 | 0.020 |
Why?
|
| Metabolomics | 1 | 2015 | 1659 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2004 | 3162 | 0.020 |
Why?
|
| Electromyography | 1 | 2011 | 1394 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1996 | 1909 | 0.020 |
Why?
|
| Collagen | 1 | 2014 | 2638 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 585 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 2358 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 957 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 2078 | 0.010 |
Why?
|
| Nematode Infections | 1 | 2004 | 19 | 0.010 |
Why?
|
| Mice, Inbred AKR | 1 | 2004 | 104 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 2416 | 0.010 |
Why?
|
| Mental Processes | 1 | 2006 | 244 | 0.010 |
Why?
|
| Social Adjustment | 2 | 1997 | 632 | 0.010 |
Why?
|
| Bacteria | 1 | 2015 | 2199 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2007 | 790 | 0.010 |
Why?
|
| Interleukin-17 | 1 | 2010 | 912 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2010 | 1475 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1996 | 4028 | 0.010 |
Why?
|
| Interleukin-5 | 1 | 2004 | 269 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2008 | 2927 | 0.010 |
Why?
|
| Attention | 1 | 2013 | 2396 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1997 | 7827 | 0.010 |
Why?
|
| Chromosome Mapping | 2 | 2001 | 4615 | 0.010 |
Why?
|
| Probability | 2 | 2000 | 2477 | 0.010 |
Why?
|
| Transfection | 1 | 2010 | 5774 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 2629 | 0.010 |
Why?
|
| Dizziness | 1 | 2005 | 259 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1997 | 6567 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 3802 | 0.010 |
Why?
|
| Home Care Services | 1 | 2008 | 648 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 705 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 584 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2010 | 2909 | 0.010 |
Why?
|
| Epitopes | 1 | 2008 | 2503 | 0.010 |
Why?
|
| Emergency Service, Hospital | 2 | 2001 | 7879 | 0.010 |
Why?
|
| Pilot Projects | 2 | 2005 | 8631 | 0.010 |
Why?
|
| Apolipoprotein E4 | 1 | 2006 | 708 | 0.010 |
Why?
|
| Outpatients | 2 | 2002 | 1597 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 11076 | 0.010 |
Why?
|
| Fear | 1 | 2010 | 1476 | 0.010 |
Why?
|
| Anxiety, Separation | 1 | 2001 | 86 | 0.010 |
Why?
|
| Nursing Homes | 1 | 2008 | 1082 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 1996 | 3708 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2010 | 1589 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2001 | 311 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2872 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 2000 | 157 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 862 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 2010 | 0.010 |
Why?
|
| Glasgow Coma Scale | 1 | 2001 | 580 | 0.010 |
Why?
|
| Vitamin D | 1 | 2013 | 3303 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2004 | 1036 | 0.010 |
Why?
|
| Heart Rate | 1 | 2011 | 4195 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 2001 | 493 | 0.010 |
Why?
|
| Medication Adherence | 1 | 2011 | 2176 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2000 | 767 | 0.010 |
Why?
|
| Emotions | 1 | 2011 | 2739 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2000 | 367 | 0.010 |
Why?
|
| Receptors, Interleukin-5 | 1 | 1998 | 20 | 0.010 |
Why?
|
| Reference Values | 1 | 2006 | 4920 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1998 | 329 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2008 | 1372 | 0.010 |
Why?
|
| Recurrence | 2 | 2003 | 8465 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 9420 | 0.010 |
Why?
|
| Linear Models | 1 | 2008 | 5871 | 0.010 |
Why?
|
| Longitudinal Studies | 2 | 2009 | 14605 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 20098 | 0.010 |
Why?
|
| Marital Status | 1 | 1999 | 426 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 9000 | 0.010 |
Why?
|
| Mortality | 1 | 2008 | 2901 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 7594 | 0.010 |
Why?
|
| Family Health | 1 | 2001 | 1257 | 0.010 |
Why?
|
| Buspirone | 1 | 1997 | 81 | 0.010 |
Why?
|
| Epilepsy | 1 | 2012 | 3290 | 0.010 |
Why?
|
| Glucose | 1 | 2008 | 4346 | 0.010 |
Why?
|
| Memory | 1 | 2006 | 2188 | 0.010 |
Why?
|
| Cross-Sectional Studies | 3 | 2006 | 26125 | 0.010 |
Why?
|
| Child | 6 | 2001 | 80153 | 0.010 |
Why?
|
| HLA-DR4 Antigen | 1 | 1995 | 22 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2000 | 2469 | 0.010 |
Why?
|
| Survival Analysis | 2 | 2000 | 10090 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 6216 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2008 | 3049 | 0.010 |
Why?
|
| Sleep | 1 | 2011 | 4768 | 0.010 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1996 | 308 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 1870 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 6425 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 16981 | 0.010 |
Why?
|
| Homozygote | 1 | 1997 | 1776 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2008 | 6630 | 0.010 |
Why?
|
| Employment | 1 | 1999 | 1118 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2004 | 3466 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 6485 | 0.010 |
Why?
|
| Educational Status | 1 | 1999 | 2522 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2001 | 2691 | 0.010 |
Why?
|
| Hospitals, General | 1 | 1996 | 798 | 0.010 |
Why?
|
| Heterozygote | 1 | 1997 | 2787 | 0.010 |
Why?
|
| Airway Obstruction | 1 | 1996 | 661 | 0.010 |
Why?
|
| Apnea | 1 | 1991 | 195 | 0.010 |
Why?
|
| United States | 1 | 2018 | 72334 | 0.010 |
Why?
|
| Research Design | 1 | 2005 | 6180 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 6075 | 0.000 |
Why?
|
| Disease Susceptibility | 1 | 1995 | 1787 | 0.000 |
Why?
|
| Disease Progression | 1 | 2005 | 13506 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 2000 | 12463 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 17635 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 2001 | 8002 | 0.000 |
Why?
|
| Mothers | 1 | 1995 | 2198 | 0.000 |
Why?
|
| Massachusetts | 1 | 1997 | 8830 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 2000 | 15266 | 0.000 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 7390 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1996 | 3600 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1991 | 1514 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 36426 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1996 | 12974 | 0.000 |
Why?
|